Video: Advancing Parkinson’s Disease Care While Maintaining Focus on Dyskinesia

Summary for Physicians: "Advancing Parkinson’s Disease Care While Maintaining Focus on Dyskinesia"

This MEDCast presentation discusses the evolving therapeutic landscape in Parkinson’s disease (PD) care, particularly in managing dyskinesia.

Key Discussion Points:

1. Development of Dyskinesia in PD:
   Both Dr. Kremens and Dr. Hauser explore the factors that contribute to the onset of dyskinesia in PD patients, particularly after long-term use of levodopa-based therapies.
2. Recent Approvals in PD Treatment:
   New treatments, including continuous subcutaneous foscarbidopa/foslevodopa (2024), apomorphine (2025), and levodopa/carbidopa extended-release (2024), have been approved. These medications are expected to improve symptom control and may influence the development of dyskinesia.
3. Impact on Dyskinesia Development:
   The panel discusses how these recent approvals are expected to affect dyskinesia rates, with a focus on the importance of timely management and patient-provider discussions about dyskinesia.
4. Treatment Options for Dyskinesia:
   The management of dyskinesia includes pharmacological options such as amantadine delayed-release/extended-release capsules, with Dr. Hauser offering insights based on clinical experience. Adjustments in treatment strategies are necessary based on the severity and type of dyskinesia a patient experiences.
5. Adjunct Treatments and Surgical Options:
   The panel explores when to consider adjunct treatments or refer patients for surgery, highlighting the importance of individualizing care as dyskinesia progresses.
6. Clinical Recommendations:
   Drs. Kremens and Hauser emphasize the importance of discussing dyskinesia with patients in 2025 and ensuring timely interventions. They offer advice on adjusting treatment plans for various manifestations of dyskinesia.

In conclusion, the session stresses the importance of staying updated on new PD treatments and maintaining a patient-centered approach to managing dyskinesia effectively.